Active substanceCocarboxylaseCocarboxylase
Similar drugsTo uncover
  • Cocarboxylase
    lyophilizate w / m in / in 
    Company DEKO, LLC     Russia
  • Cocarboxylase
    lyophilizate w / m 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase
    lyophilizate w / m in / in 
  • Cocarboxylase-Ferein
    lyophilizate w / m in / in 
    BRYNTSALOV-A, CJSC     Russia
  • Cocarboxylase-Ellara®
    lyophilizate w / m in / in 
    ELLARA, LTD.     Russia
  • Cocarboxylase hydrochloride
    lyophilizate w / m in / in 
  • Dosage form: & nbsplyophilizate for the preparation of solution for intravenous and intramuscular administration
    Composition:

    Composition (per ampoule):

    Active substance:

    Cocarboxylase hydrochloride - 50 mg.

    Excipient:

    Sodium carbonate - 8 mg.

    Description:

    Lyophilized powder or dry porous hygroscopic mass of white with a characteristic odor.

    Pharmacotherapeutic group:Metabolic means
    ATX: & nbsp

    A.11.D.A   Vitamin B1

    Pharmacodynamics:

    Cocarboxylase is a coenzyme of thiamine (vitamin B1), in the body phosphorylated with the formation of mono-, di- and triphosphate esters, is part of the enzymes that catalyze the carboxylation and decarboxylation of alpha-keto acids, pyruvic acid. Endogenous cocarboxylase is formed in the body from exogenous thiamine by phosphorylation, however, the properties of cocarboxylase do not fully correspond to the properties of thiamine and it can not be used for the prevention and treatment of hypo- and avitaminosis B1. Cocarboxylase improves the absorption of glucose, trophic tissue of the nervous system, contributes to the normalization of the function of the cardiovascular system. Reduces the level of lactic and pyruvic acids in the blood (increasing the content of these acids leads to the development of acidosis and acidosis).

    Pharmacokinetics:

    After parenteral administration cocarboxylase well absorbed. In the body it is not deposited. Excreted in urine.

    Indications:

    Cocarboxylase is prescribed as a part of complex therapy for hepatic and renal insufficiency, diabetic precoma and coma, diabetic ketoacidosis, chronic heart failure and cardiac rhythm disturbances, peripheral neuritis. Children are appointed for the same indications. In newborns, the drug is also used as part of complex therapy of conditions accompanied by hypoxia and acidosis, including asphyxia of newborns, hypoxic encephalopathy, circulatory insufficiency, pneumonia,sepsis.

    Contraindications:

    Hypersensitivity to the drug.

    Pregnancy and lactation:

    Data on the safety of the drug when it is administered to pregnant women are not available. Due to the insufficient number of studies, the drug should not be given to pregnant and lactating women.

    Dosing and Administration:

    Kokarboksilazu enter intramuscularly and intravenously (struyno or drip). The contents of the ampoule (50 mg) are dissolved immediately before injection into 2 ml of water for injection. At intravenous jet introduction volume of a solution lead up to 10-20 ml, at drop introduction to 200-400 ml, adding 0,9% a solution of sodium of a chloride or a solution of a dextrose (glucose).

    With violations of the heart rhythm prescribed 100-200 mg per day for 15-30 days. In chronic heart failure: 50 mg 2 hours before the use of digitalis preparations 2-3 times a day.

    In diabetes (ketoacidosis, coma), the daily dose is 100 mg.

    In acute renal and hepatic insufficiency intravenously injected 100-150 mg 3 times a day or drip, previously dissolved in a 5% solution of dextrose (glucose) to 100-150 mg per day.

    With peripheral neuritis, intramuscularly administered at a dose of 50-100 mg per day for 1-1.5 months.

    Children are given intramuscularly, intravenously (drip or jet). Depending on the severity of the condition and clinical symptoms, it is prescribed from 25 to 50 mg per day.

    The course of treatment is from 3-7 to 15-30 days. The newborn is injected intravenously (slowly) 10 mg per 1 kg of body weight once a day.

    Side effects:

    Allergic reactions are possible (hives, itchy skin); when intramuscular injection - hyperemia, itching, edema (at the injection site).

    Overdose:

    There is no information about overdose.

    Interaction:

    Kokarboksilaza increases the cardiotonic action of cardiac glycosides and improves their tolerability.

    Special instructions:

    Without features.

    Effect on the ability to drive transp. cf. and fur:

    The effect of the drug on the ability to drive vehicles and mechanisms has not been studied.

    Form release / dosage:

    Lyophilizate for the preparation of solution for intravenous and intramuscular injection 50 mg.

    Packaging:

    5 ampoules of the drug are placed in a contour cell pack.

    1 or 2 contourcells with the preparation together with the instructions for use, a ampoule or ampoule ampoule knife is placed in a pack of cardboard.

    5 ampoules with the preparation complete with 5 ampoules of the solvent (Water for injection according to 2 ml) in separate outline cell packs along with the instructions for use, with an ampoule or ampoule scraping knife, put in a pack of cardboard.

    When packaging ampoules that have a break ring or an opening point, the ampoule knife or the ampoule scapegrator is not put in.

    Packing for hospitals. According to 50, 100 contour cell packs with ampoules of the preparation together with instructions for use in the number of copies, equal to the number of contiguous cell packs are placed in a box of corrugated cardboard.

    25 contour cell packs with ampoules of the preparation with 25 contour cell packs with solvent ampoules (Water for Injection) or 50 circuit cells with ampoules of the preparation with 50 circuit cell packs with solvent ampoules (Water for Injection) together with instructions for use in the amount copies equal to the number of contour mesh packages are placed in a box of corrugated cardboard.

    Storage conditions:

    Store at a temperature not exceeding 20 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-004186
    Date of registration:15.03.2017
    Expiration Date:15.03.2022
    The owner of the registration certificate:Kursk Biofactory - BIOK, FKPKursk Biofactory - BIOK, FKP Russia
    Manufacturer: & nbsp
    Information update date: & nbsp30.01.2018
    Illustrated instructions
      Instructions
      Up